Beijing-Sana
The National Intellectual Property Rights Administration granted the first patent for a vaccine against the emerging corona virus “Covid 19” in China.
The patent was filed with a research team at the Military Academy of Science and Technology and Cansino Biology Corporation, a Chinese high-tech biological drug company, according to a report published by the People's Daily.
The team developed the recombinant Covid 19 vaccine with the modified adenovirus as the vector.
And last March, this vaccine became the first vaccine in China to be approved to enter the clinical trial stage.
According to the patent summary, this vaccine shows good immunity on mouse models and can stimulate a strong cellular and humoral immune response in a short period of time and can be quickly produced on a large scale to counteract the Corona outbreak.
The vaccine has now completed the first and second phase of clinical trials, where its safety and ability to stimulate immunity has been confirmed, according to the report.